Multiplexed quantification of insulin and C-peptide by LC-MS/MS without the use of antibodies
Open Access
- 10 June 2022
- journal article
- research article
- Published by Stanford University Press in Journal of Mass Spectrometry and Advances in the Clinical Lab
- Vol. 25, 19-26
Abstract
The measurement of insulin and C-peptide provides a valuable tool for the clinical evaluation of hypoglycemia. In research, these biomarkers are used together to better understand hyperinsulinemia, hepatic insulin clearance, and beta cell function. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is an attractive approach for the analysis of insulin and C-peptide because the platform is specific, can avoid certain limitations of immunoassays, and can be multiplexed. Previously described LC-MS/MS methods for the simultaneous quantification of insulin and C-peptide measure the intact analytes and most have relied on immunoaffinity enrichment. These approaches can be limited in terms of sensitivity and interference from auto-antibodies, respectively. We have developed a novel method that does not require antibodies and uses proteolytic digestion to yield readily ionizable proteotypic peptides that enables the sensitive, specific, and simultaneous quantitation of insulin and C-peptide. Serum samples were precipitated with acetonitrile. Analytes were enriched using solid phase extraction and then digested with endoproteinase Glu-C. Surrogate peptides for insulin and C-peptide were analyzed using targeted LC-MS/MS. Inter-day imprecision was below 20 %CV and linearity was observed down to the lower limit of quantitation for both analytes (insulin = 0.09 ng/mL, C-peptide = 0.06 ng/mL). Comparison to a commercially available insulin immunoassay (Beckman Coulter UniCel DxI 600 Access) revealed a 30% bias between methods. A novel LC-MS/MS method for the simultaneous analysis of insulin and C-peptide using Glu-C digestion was developed and evaluated. A detailed standard operating procedure is provided to help facilitate implementation in other laboratories.Keywords
Funding Information
- Diabetes Research Center, University of Washington
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK017047)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK121289)
- University of Washington
This publication has 30 references indexed in Scilit:
- Multidimensional LC-MS/MS Enables Simultaneous Quantification of Intact Human Insulin and Five Recombinant Analogs in Human PlasmaAnalytical Chemistry, 2013
- Quantitative Insulin Analysis Using Liquid Chromatography–Tandem Mass Spectrometry in a High-Throughput Clinical LaboratoryClinical Chemistry, 2013
- Insulin Assay StandardizationDiabetes Care, 2010
- Standardization of Insulin Immunoassays: Report of the American Diabetes Association WorkgroupClinical Chemistry, 2007
- Qualitative Determination of Synthetic Analogues of Insulin in Human Plasma by Immunoaffinity Purification and Liquid Chromatography−Tandem Mass Spectrometry for Doping Control PurposesAnalytical Chemistry, 2005
- Cross-Reactivity of Three Recombinant Insulin Analogs with Five Commercial Insulin ImmunoassaysClinical Chemistry, 2004
- The Interference of Insulin Antibodies in Insulin Immunometric AssaysClinical Chemistry and Laboratory Medicine (CCLM), 2002
- Insulin Degradation: Progress and Potential*Endocrine Reviews, 1998
- Intraorganellar calcium and pH control proinsulin cleavage in the pancreatic β cell via two distinct site-specific endopeptidasesNature, 1988
- Kinetics of human connecting peptide in normal and diabetic subjects.Journal of Clinical Investigation, 1978